Bioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. The company also provides product research and development services, and telemedicine services. In addition, it operates BLS Clinics, a telehealth platform. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Metrics to compare | BXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBXNPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.1x | −0.9x | 11.6x | |
PEG Ratio | 0.01 | 0.00 | 0.03 | |
Price/Book | 7.4x | 0.9x | 1.5x | |
Price / LTM Sales | 2.8x | 1.0x | 0.9x | |
Upside (Analyst Target) | - | 51.0% | 22.6% | |
Fair Value Upside | Unlock | 6.2% | 9.6% | Unlock |